What is Selectis Health Inc's earnings per share (EPS)?

Selectis Health Inc (GBCS) reported diluted earnings per share of -$0.34 for fiscal year 2025. This represents a 57.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Selectis Health Inc Financials

GBCS

Trailing 12 months to June 30, 2026

Revenue $32.5M -21.3% YoY

Net Income $14.6M +563.8% YoY

EPS (Diluted) $4.23 +506.7% YoY

Free Cash Flow -$3.9M -256.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 24, 2026 Currency USD FYE December

Selectis Health Inc (GBCS) reported $32.5M in revenue over the twelve months to Jun 30, 2026, down 21.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GBCS FY2025 2026-08-30

Operating cash flow recovery masks a business still financed by liabilities, with losses eroding equity and short-term financial flexibility.

FY2025 produced positive operating cash flow of $1.9M despite a net loss of $1.0M, reversing FY2024's $1.8M operating cash outflow. After $443K of capital spending, free cash flow remained $1.4M, so the year's cash improvement came from non-earnings cash effects rather than profitability.

FY2025 revenue rose to $41.4M while SG&A fell to $8.9M, helping operating losses narrow; this supports cost discipline and expense absorption, not a claim about gross-margin improvement because gross profit is not reported. Operating margin improved from -6.9% in FY2024 to -3.8% in FY2025, confirming better expense absorption even though operations remained loss-making.

Long-term debt fell from $31.1M in FY2021 to $13.4M in FY2025, indicating debt reduction rather than expansion financed the recent balance-sheet change. Yet total liabilities exceeded assets by $6.6M in FY2025 and the current ratio was 0.3x, so deleveraging has not restored positive equity or near-term balance-sheet flexibility.

Financial Health Signals

Financial health score not available

Selectis Health Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-0.21

Selectis Health Inc scores -0.21, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($16.7M) relative to total liabilities ($39.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

Selectis Health Inc passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Selectis Health Inc reported a net loss of $1.0M while generating $1.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Selectis Health Inc reported an operating loss of $1.6M against $1.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$41.4M

YoY+4.9%

5Y CAGR+14.6%

Selectis Health Inc generated $41.4M in revenue in fiscal year 2025. This represents an increase of 4.9% from the prior year.

EBITDA

-$90K

YoY+92.2%

Selectis Health Inc's EBITDA was -$90K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 92.2% from the prior year.

Net Income

-$1.0M

YoY+58.1%

Selectis Health Inc reported -$1.0M in net income in fiscal year 2025. This represents an increase of 58.1% from the prior year.

EPS (Diluted)

-$0.34

YoY+57.5%

Selectis Health Inc earned -$0.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 57.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.4M

YoY+177.3%

5Y CAGR-3.8%

Selectis Health Inc generated $1.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 177.3% from the prior year.

Cash & Debt

$1.0M

YoY+48.7%

5Y CAGR-22.3%

10Y CAGR+30.4%

Selectis Health Inc held $1.0M in cash against $13.4M in long-term debt as of fiscal year 2025.

Shares Outstanding

YoY0.0%

Selectis Health Inc had 3M shares outstanding in fiscal year 2025. That is unchanged from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Operating Margin

-3.8%

YoY+3.1pp

5Y CAGR-19.9pp

Selectis Health Inc's operating margin was -3.8% in fiscal year 2025, reflecting core business profitability. This is up 3.1 percentage points from the prior year.

Net Margin

-2.5%

YoY+3.7pp

5Y CAGR-16.6pp

Selectis Health Inc's net profit margin was -2.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.7 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

Capital Expenditures

$444K

YoY+1130.1%

5Y CAGR-14.8%

10Y CAGR-2.9%

Selectis Health Inc invested $444K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1130.1% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

GBCS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

GBCS quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$32.5M	$41.4M+4.9%	$39.5M+7.4%	$36.8M-9.4%	$40.6M+38.6%	$29.3M+39.9%	$20.9M+202.0%	$6.9M+91.3%	$3.6M+15.8%	$3.1M	N/A	N/A	N/A	$3.1M+0.8%	$3.1M-43.6%	$5.5M
SG&A Expenses	$8.5M	$8.9M-3.9%	$9.2M-7.2%	$10.0M+26.7%	$7.9M+33.1%	$5.9M+183.0%	$2.1M+60.8%	$1.3M+10.2%	$1.2M+17.7%	$1.0M-44.1%	$1.8M+6.5%	$1.7M+107.9%	$809K+112.0%	$382K-7.0%	$411K+139.0%	$172K
Operating Income	-$4.1M	-$1.6M+42.7%	-$2.7M+69.5%	-$9.0M-3026.8%	-$287K+60.7%	-$729K-121.6%	$3.4M+159.5%	$1.3M+282.6%	$340K-26.8%	$465K+905.4%	-$58K+95.7%	-$1.3M-106.1%	-$652K-5610.6%	-$11K+86.0%	-$82K+93.6%	-$1.3M
Interest Expense	$2.1M	$1.7M-15.7%	$2.0M-5.8%	$2.2M-2.6%	$2.2M-10.7%	$2.5M+16.7%	$2.1M+0.1%	$2.1M-0.1%	$2.1M-3.5%	$2.2M+185.7%	-$2.6M+8.0%	-$2.8M-190.0%	-$969K-292.7%	$503K+33.8%	$376K+245.1%	$109K
Income Tax	N/A	$800	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$14.6M	-$1.0M+58.1%	-$2.4M+39.0%	-$4.0M-65.7%	-$2.4M-6.4%	-$2.3M-176.2%	$3.0M+443.1%	-$862K+56.7%	-$2.0M+33.5%	-$3.0M-160.2%	-$1.2M+65.5%	-$3.3M-345.7%	$1.4M+175.1%	-$1.8M-113.8%	-$845K+38.7%	-$1.4M
EPS (Diluted)	$4.23	-$0.34+57.5%	-$0.80+38.9%	-$1.31-65.8%	-$0.79+3.7%	-$0.82-186.3%	$0.95	-$0.03+62.5%	-$0.08+33.3%	-$0.12-140.0%	-$0.05+66.7%	-$0.15-350.0%	$0.06	N/A	-$0.13+40.9%	-$0.22

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$4.7M-35.1%	$7.3M-24.6%	$9.7M-10.8%	$10.8M+3.8%	$10.4M-0.4%	$10.5M+0.9%	$10.4M+3.8%	$10.0M
SG&A Expenses	$2.1M-1.2%	$2.1M-0.6%	$2.1M-0.2%	$2.1M-4.0%	$2.2M-5.4%	$2.4M+4.3%	$2.3M-5.4%	$2.4M
Operating Income	-$2.1M-66.4%	-$1.3M-219.1%	-$396K-33.2%	-$297K+34.1%	-$450K-6.8%	-$422K-333.6%	-$97K+91.7%	-$1.2M
Interest Expense	$213K-77.0%	$924K+22.9%	$752K+265.5%	$206K-9.0%	$226K-58.4%	$543K+52.6%	$356K-25.1%	$475K
Income Tax	$471K+15.1%	$410K	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$8.1M+24.5%	$6.5M+911.6%	-$804K-206.9%	$752K+344.3%	-$308K+53.0%	-$656K-13.8%	-$576K+64.1%	-$1.6M
EPS (Diluted)	$2.35+23.7%	$1.90+830.8%	-$0.26-208.3%	$0.24+340.0%	-$0.10+54.5%	-$0.22-10.0%	-$0.20+61.5%	-$0.52

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

GBCS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

GBCS quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$32.6M-2.6%	$33.4M-17.8%	$40.7M-4.3%	$42.5M-9.4%	$46.9M+2.2%	$45.9M+15.2%	$39.9M+4.1%	$38.3M+0.2%	$38.2M+1.8%	$37.5M-8.8%	$41.2M-11.5%	$46.5M+774.1%	$5.3M+38.2%	$3.8M+8.6%	$3.5M
Current Assets	$7.6M+114.8%	$3.5M-28.8%	$5.0M-0.1%	$5.0M-37.7%	$8.0M+28.4%	$6.2M	N/A	N/A	N/A	N/A	N/A	N/A	$495K-38.4%	$803K-6.7%	$861K
Cash & Equivalents	$1.0M+48.7%	$680K-54.2%	$1.5M+4.5%	$1.4M-63.9%	$3.9M+10.4%	$3.6M+456.4%	$641K-41.7%	$1.1M+611.8%	$155K-73.3%	$578K+713.8%	$71K-86.7%	$534K+123.7%	$239K-51.5%	$492K-7.3%	$531K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$8K-65.3%	$24K+6.0%	$23K
Accounts Receivable	$2.3M-13.0%	$2.6M+25.1%	$2.1M-28.0%	$2.9M-17.2%	$3.5M+81.5%	$1.9M+62.6%	$1.2M+612.7%	$167K+88.4%	$88K	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M+183.8%	$379K	N/A	N/A	N/A	N/A	$1.8M+1650.5%	$100K	N/A	N/A
Total Liabilities	$39.2M+0.9%	$38.9M-10.9%	$43.6M+5.1%	$41.5M-5.2%	$43.8M+2.6%	$42.7M+8.1%	$39.5M+5.9%	$37.3M+3.8%	$35.9M+8.9%	$33.0M-9.7%	$36.6M-1.9%	$37.3M+612.3%	$5.2M+149.1%	$2.1M+16.5%	$1.8M
Current Liabilities	$25.7M+30.8%	$19.6M+8.2%	$18.1M+165.0%	$6.8M-41.9%	$11.8M-50.1%	$23.6M	N/A	N/A	N/A	N/A	N/A	N/A	$2.5M+52.3%	$1.7M+24.2%	$1.3M
Long-Term Debt	$13.4M-29.9%	$19.1M-24.0%	$25.2M-26.8%	$34.4M+10.8%	$31.1M+64.9%	$18.8M-50.4%	$38.0M+3.8%	$36.6M+4.2%	$35.1M+9.6%	$32.0M-10.5%	$35.8M	N/A	$0	$0-100.0%	$155K
Total Equity	-$6.6M-13.8%	-$5.8M-96.1%	-$3.0M-411.1%	$953K-69.3%	$3.1M-9.1%	$3.4M+497.6%	$571K-51.7%	$1.2M-52.0%	$2.5M-47.7%	$4.7M-21.8%	$6.0M-43.2%	$10.6M+12135.2%	$87K-95.0%	$1.7M+0.5%	$1.7M
Retained Earnings	-$21.2M-5.2%	-$20.2M-13.8%	-$17.7M-29.1%	-$13.7M-21.4%	-$11.3M-25.3%	-$9.0M+24.5%	-$12.0M-8.1%	-$11.1M-22.3%	-$9.0M-50.3%	-$6.0M-24.4%	-$4.8M-2377.0%	$213K+594.7%	-$43K+99.7%	-$14.8M-6.5%	-$13.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$31.5M+4.8%	$30.0M-7.9%	$32.6M-2.1%	$33.3M-1.1%	$33.6M-2.6%	$34.5M+3.3%	$33.4M-1.4%	$33.9M
Current Assets	$12.0M+21.9%	$9.8M+29.5%	$7.6M+91.7%	$4.0M-1.2%	$4.0M-15.6%	$4.7M+34.4%	$3.5M-0.1%	$3.5M
Cash & Equivalents	$7.7M+501.2%	$1.3M+27.2%	$1.0M+142.5%	$417K-25.5%	$560K-56.5%	$1.3M+89.4%	$680K-62.7%	$1.8M
Accounts Receivable	$1.4M-42.8%	$2.5M+9.3%	$2.3M-28.7%	$3.2M+5.0%	$3.0M+5.8%	$2.9M+9.9%	$2.6M+37.4%	$1.9M
Goodwill	$379K0.0%	$379K-64.8%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M
Total Liabilities	$23.5M-22.1%	$30.2M-23.1%	$39.2M+0.7%	$38.9M-2.8%	$40.0M-1.5%	$40.6M+4.5%	$38.9M+0.2%	$38.8M
Current Liabilities	$11.8M-28.0%	$16.3M-36.4%	$25.7M+26.5%	$20.3M-4.4%	$21.2M-1.3%	$21.5M+9.6%	$19.6M-2.8%	$20.2M
Long-Term Debt	$11.6M-12.9%	$13.3M-0.6%	$13.4M-27.6%	$18.5M-1.0%	$18.7M-1.6%	$19.0M-0.7%	$19.1M+3.6%	$18.5M
Total Equity	$8.0M+5689.1%	-$143K+97.8%	-$6.6M-17.0%	-$5.7M+16.9%	-$6.8M-4.9%	-$6.5M-11.5%	-$5.8M-20.2%	-$4.8M
Retained Earnings	-$6.6M+55.1%	-$14.7M+30.7%	-$21.2M-4.0%	-$20.4M+3.5%	-$21.2M-1.5%	-$20.9M-3.3%	-$20.2M-2.9%	-$19.6M

Not reported in any period shown, so not listed: Inventory.

GBCS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

GBCS quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$3.4M	$1.9M+203.2%	-$1.8M-440.0%	$537K+275.9%	-$305K-12.6%	-$271K-109.9%	$2.7M+214.7%	$869K+703.2%	$108K-50.4%	$218K+143.1%	-$507K-1543.0%	-$31K+95.1%	-$627K-1677.1%	$40K+278.3%	-$22K-107.4%	$301K
Capital Expenditures	$470K	$444K+1130.1%	$36K+21.0%	$30K-86.6%	$222K-57.2%	$520K-47.3%	$986K-40.9%	$1.7M+118.7%	$763K-11.3%	$860K+174.3%	$314K-47.6%	$598K-89.5%	$5.7M+29498.1%	$19K-76.5%	$82K+100.2%	$41K
Free Cash Flow	-$3.9M	$1.4M+177.3%	-$1.9M-467.1%	$507K+196.1%	-$528K+33.3%	-$791K-145.2%	$1.7M+318.6%	-$800K-22.1%	-$655K-2.0%	-$642K+21.8%	-$821K-30.5%	-$629K+90.1%	-$6.3M-31082.6%	$20K+119.6%	-$105K-140.2%	$260K
Investing Cash Flow	$13.7M	-$444K-118.1%	$2.4M+8315.9%	-$30K+86.6%	-$222K+57.2%	-$520K+67.0%	-$1.6M+34.7%	-$2.4M-304.6%	-$595K+52.1%	-$1.2M-155.9%	$2.2M+530.8%	$352K+104.9%	-$7.1M-39412.0%	-$18K+96.9%	-$582K-261.5%	-$161K
Financing Cash Flow	-$3.7M	-$977K+36.5%	-$1.5M-148.4%	-$619K+66.5%	-$1.8M-215.2%	$1.6M-12.0%	$1.8M+49.0%	$1.2M+48.9%	$822K-1.9%	$838K+169.3%	-$1.2M-54.1%	-$784K-111.0%	$7.1M+2689.4%	-$275K-148.7%	$566K+491.4%	-$144K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$441K+6.3%	$415K	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$102K	N/A	$133K	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.0M+11.1%	-$2.3M-455.6%	$644K+130.0%	$280K+461.9%	-$77K-107.5%	$1.0M+344.6%	-$423K+65.5%	-$1.2M
Capital Expenditures	$32K-91.6%	$377K+566.2%	$57K+1237.7%	$4K-97.4%	$164K-25.4%	$219K+2129.0%	$10K+1449.0%	-$635
Free Cash Flow	-$2.1M+22.5%	-$2.7M-554.1%	$587K+113.0%	$276K+214.5%	-$241K-129.5%	$816K+288.4%	-$433K+64.7%	-$1.2M
Investing Cash Flow	$8.7M+73.1%	$5.0M+8972.6%	-$57K-1237.7%	-$4K+97.4%	-$164K+25.4%	-$219K-2129.0%	-$10K-1649.0%	$635
Financing Cash Flow	-$207K+93.4%	-$3.1M-7444.3%	$42K+111.0%	-$384K+15.3%	-$453K-148.2%	-$182K-7207.1%	$3K+100.3%	-$974K
Dividends Paid	N/A	$8K	N/A	$8K0.0%	$8K-50.0%	$15K	N/A	$8K

Not reported in any period shown, so not listed: Share Buybacks.

GBCS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

GBCS quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Margin	-3.8%+3.1pp	-6.9%+17.5pp	-24.4%-23.7pp	-0.7%+1.8pp	-2.5%-18.6pp	16.1%-2.6pp	18.8%+9.4pp	9.4%-5.5pp	14.8%	N/A	N/A	N/A	-0.4%+2.3pp	-2.6%+20.4pp	-23.0%
Net Margin	-2.5%+3.7pp	-6.1%+4.7pp	-10.8%-4.9pp	-5.9%+1.8pp	-7.7%-21.8pp	14.1%+26.5pp	-12.4%+42.5pp	-55.0%+40.8pp	-95.7%	N/A	N/A	N/A	-57.6%-30.4pp	-27.2%-2.1pp	-25.0%
Return on Equity	N/A	N/A	N/A	-251.4%-178.9pp	-72.6%-159.2pp	86.6%+237.4pp	-150.8%+17.6pp	-168.4%-46.9pp	-121.5%-97.1pp	-24.4%+30.9pp	-55.3%-68.1pp	12.8%+2096.3pp	-2083.5%-2035.1pp	-48.4%+30.9pp	-79.3%
Return on Assets	-3.1%+4.1pp	-7.2%+2.5pp	-9.8%-4.1pp	-5.6%-0.8pp	-4.8%-11.2pp	6.4%+8.6pp	-2.2%+3.0pp	-5.2%+2.6pp	-7.8%-4.8pp	-3.1%+5.0pp	-8.1%-11.0pp	2.9%+36.9pp	-34.0%-12.0pp	-22.0%+17.0pp	-39.0%
Current Ratio	0.30+0.1x	0.18-0.1x	0.27-0.5x	0.720.0x	0.68+0.4x	0.26	N/A	N/A	N/A	N/A	N/A	N/A	0.20-0.3x	0.49-0.2x	0.65
Debt-to-Equity	N/A	N/A	N/A	36.10+26.1x	10.01+4.5x	5.52-61.0x	66.48+35.5x	30.94+16.7x	14.25+7.4x	6.80+0.9x	5.94+2.4x	3.51+3.5x	0.000.0x	0.00-0.1x	0.09
FCF Margin	3.5%+8.2pp	-4.7%-6.1pp	1.4%+2.7pp	-1.3%+1.4pp	-2.7%-11.1pp	8.3%+19.9pp	-11.5%+6.5pp	-18.1%+2.4pp	-20.5%	N/A	N/A	N/A	0.7%+4.0pp	-3.4%-8.1pp	4.7%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	-44.5%-27.1pp	-17.3%-13.2pp	-4.1%-1.3pp	-2.7%+1.6pp	-4.3%-0.3pp	-4.0%-3.1pp	-0.9%+10.8pp	-11.7%
Net Margin	171.8%	89.5%+97.8pp	-8.3%-15.3pp	6.9%+9.9pp	-2.9%+3.3pp	-6.3%-0.7pp	-5.5%+10.5pp	-16.0%
Return on Equity	101.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	25.8%+4.1pp	21.8%+24.2pp	-2.5%-4.7pp	2.3%+3.2pp	-0.9%+1.0pp	-1.9%-0.2pp	-1.7%+3.0pp	-4.7%
Current Ratio	1.02+0.4x	0.60+0.3x	0.30+0.1x	0.190.0x	0.190.0x	0.220.0x	0.180.0x	0.17
Debt-to-Equity	1.46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	-43.7%-7.1pp	-36.6%-42.7pp	6.1%+3.5pp	2.5%+4.9pp	-2.3%-10.1pp	7.8%+11.9pp	-4.2%+8.1pp	-12.3%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Note: Shareholder equity is negative (-$6.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.30), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Veltex VLXC

$4.9M

Xcelerate Inc XCRT

$4.8M

Revitalist Lifes RVLWF

$5.4M

Healthlynked HLYK

$8.1M

Biocorrx Inc BICX

$6.0M

Where Selectis Health Inc Ranks

Frequently Asked Questions

What is Selectis Health Inc's annual revenue?

Selectis Health Inc (GBCS) reported $41.4M in total revenue for fiscal year 2025. This represents a 4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Selectis Health Inc's revenue growing?

Selectis Health Inc (GBCS) revenue grew by 4.9% year-over-year, from $39.5M to $41.4M in fiscal year 2025.

Is Selectis Health Inc profitable?

No, Selectis Health Inc (GBCS) reported a net income of -$1.0M in fiscal year 2025, with a net profit margin of -2.5%.

What is Selectis Health Inc's EBITDA?

Selectis Health Inc (GBCS) had EBITDA of -$90K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Selectis Health Inc have?

As of fiscal year 2025, Selectis Health Inc (GBCS) had $1.0M in cash and equivalents against $13.4M in long-term debt.

What is Selectis Health Inc's operating margin?

Selectis Health Inc (GBCS) had an operating margin of -3.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Selectis Health Inc's net profit margin?

Selectis Health Inc (GBCS) had a net profit margin of -2.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Selectis Health Inc's free cash flow?

Selectis Health Inc (GBCS) generated $1.4M in free cash flow during fiscal year 2025. This represents a 177.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Selectis Health Inc's operating cash flow?

Selectis Health Inc (GBCS) generated $1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Selectis Health Inc's total assets?

Selectis Health Inc (GBCS) had $32.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Selectis Health Inc's capital expenditures?

Selectis Health Inc (GBCS) invested $444K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Selectis Health Inc have outstanding?

Selectis Health Inc (GBCS) had 3M shares outstanding as of fiscal year 2025.

What is Selectis Health Inc's current ratio?

Selectis Health Inc (GBCS) had a current ratio of 0.30 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Selectis Health Inc's return on assets (ROA)?

Selectis Health Inc (GBCS) had a return on assets of -3.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Selectis Health Inc's debt-to-equity ratio negative or not reported?

Selectis Health Inc (GBCS) has negative shareholder equity of -$6.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Selectis Health Inc's Altman Z-Score?

Selectis Health Inc (GBCS) has an Altman Z-Score of -0.21, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Selectis Health Inc's Piotroski F-Score?

Selectis Health Inc (GBCS) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Selectis Health Inc's earnings high quality?

Selectis Health Inc (GBCS) reported a net loss of $1.0M while generating $1.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Selectis Health Inc cover its interest payments?

Selectis Health Inc (GBCS) reported an operating loss of $1.6M against $1.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.